参考文献/References:
{1]叶胜龙.2013年肝癌领域新进展.中华肝脏病杂志,2014,22（1）：2-4.
[2]Chen W, Zheng R, Zhang S, et al.Report of incidence and mortality in China cancer Registries,2009. Chin J Cancer Res,2013,25(1):10-21.
[3]Chen WQ, Zheng RS, Zhan SW.Liver cancer incidence and motality in China,2009. Chin J Cancer,2013, 32(4):162-169.
[4]黄志强，主编.黄志强肝胆外科讲义.第1版.北京：人民卫生出版社,2013.23-44.
[5]吴孟超，吴在德，主编.黄家驷外科学.第7版.北京：人民卫生出版社,2008.1693.
[6]汤钊猷.肝癌研究的变迁与趋势.临床肝胆病杂志，2014,30（3）：193-196.
[7]Chau GY. Resection of hepatitis B virusrelated hepatocellular carcinoma: evolving strategies and emerging therapies to improve outcome. World J Gastroenterol,2014,20(35)：12473-12484.
[8]秦叔逵，吴穷.肝细胞癌系统治疗的进步.中国处方药,2013，11（5）：29-33.
[9]中华医学会肝病学分会，中华医学会感染病学分会.慢性乙型肝炎防治指南（2010 年版）.中国肝脏病杂志,2011,19（1）：13-24.
[10]European Association for the Study of the liver.EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol,2012,57（1）:167-185.
[11]Liaw YF, Kao JH, Piratvisuth T, et al. AsianPacific consensus statement on the management of chronic hepatitis B:a 2012 update. Hepatology International,2012,6(3):531-561.
[12]Lok AS，McMahon BJ. Chronic hepatitis B:update 2009. Hepatology,2009,50(3):661-662.
[13]PeckRadosavljevic M. Drug therapy for advancedstage liver cancer. Liver Cancer,2014,3(2):125-131.
[14]Lencioni R, Kudo M, Ye SL, et al. GIDEON (global investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafenib): second interim analysis. Int J Clin Pract, 2014,68(5):609-617.
[15]Qin S,Cheng Y, Liang J, et al. Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study. Oncologist,2014,19(11):1169-1178.
[16]Chen CJ, Yang HI, Su J，et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA,2006,295(1):65-73.
[17]Kawanaka M, Nishino K, Nakamura J, et al. Quantitative levels of hepatitis B virus DNA and surface antigen and the risk of hepatocellular carcinoma in patients with hepatitis B receiving longterm nucleos(t)ide analogue therapy. Liver Cancer,2014,3(1):41-52.
[18]肝细胞癌抗病毒治疗专家组.HBV/HCV相关性肝细胞癌抗病毒治疗专家共识.中华肝脏病杂志，2014,22（5）:321-326.
[19]Lai CL, Yuen MF. Prevention of hepatitis B virusrelated hepatocellular carcinoma with antiviral therapy.Hepatology,2013,57(1):399-408.
[20]陈新月，柳雅立.干扰素联合核苷（酸）类似物治疗慢性乙型肝炎的评价与探索.中华传染病杂志，2014,32（1）：55-58.
[21]Huang G, Lai EC,Lai WY, et al. Posthepatectomy HBV reactivation in hepatitis Brelated hepatocellular carcinoma influences postoperative survival in patients with preoperative low HBVDNA levels. Ann Surg,2013,257(3):490-505.
[22]Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during longterm lamivudine therapy. Gastroenterology, 2003,124(1):105-117.
[23]Hadziyannis SJ, Tassopoulos NC, Heathcot EJ, et al. Longterm therapy with adefovir dipivoxil for HBeAg negative chronic hepatitis B for up to 5 years. Gastroenterology, 2006,131(6) :1743-1751.
[24]Marcellin P, Chang TT, Lim SG, et al. Longterm efficacy and safety of adefovir dipivoxil for the treatment of hepatitis Be antigenpositive chronic hepatitis B. Hepatology,2008,48(3):750-758.
[25]Liaw YF. Reversal of cirrhosis: an achievable goal of hepatitis B antiviral therapy. J Hepatol ,2013,59(4):880-881.
[26]Heo J, Reid T, Ruo L, et al. Randomized dosefinding clinical trial of oncolytic immunotherapeutic vaccinia JX594 in liver cancer. Nat Med, 2013,19(3):329-336.
[27]杜运生，周宁新，主编.肝癌外科治疗进展. 第1版. 北京：人民军医出版社,2012,164.
[28]Choi C, Choi GH, Kim TH, et al. Multimodality management for Barcelona Clinic Liver Cancer Stage C hepatocellular carcinoma. Liver cancer,2014,3(3-4):405-416.